Chemogenetics revealed: DREADD occupancy and activation via converted clozapine

Science

Volumn 357, Issue 6350, 2017, Pages 503-507

  Gomez, Juan L ^a   Bonaventura, Jordi ^a   Lesniak, Wojciech ^b   Mathews, William B ^b   Sysa Shah, Polina ^b   Rodriguez, Lionel A ^a   Ellis, Randall J ^a   Richie, Christopher T ^a   Harvey, Brandon K ^a   Dannals, Robert F ^b   Pomper, Martin G ^b   Bonci, Antonello ^a   Michaelides, Michael ^a,b  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 11; CLOZAPINE N OXIDE; DESIGNER DRUG; DESIGNER RECEPTORS EXCLUSIVELY ACTIVATED BY DESIGNER DRUG; MUSCARINIC RECEPTOR; UNCLASSIFIED DRUG; CLOZAPINE; CLOZAPINE N-OXIDE; MUSCARINIC M3 RECEPTOR; MUSCARINIC M4 RECEPTOR;

BRAIN; CELLS AND CELL COMPONENTS; CHEMICAL ANALYSIS; DRUG; GENE EXPRESSION; TECHNOLOGICAL CHANGE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN TISSUE; CHEMOGENETICS; COMPETITIVE BINDING ASSAY; CONTROLLED STUDY; GENETICS; HUMAN; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; ANALOGS AND DERIVATIVES; ANIMAL; BINDING COMPETITION; BRAIN; DRUG EFFECTS; GENETIC PROCEDURES; HEK293 CELL LINE; METABOLISM; NERVE CELL; TRANSGENIC MOUSE;

ANIMALIA;

ANIMALS; BINDING, COMPETITIVE; BRAIN; CLOZAPINE; DESIGNER DRUGS; GENETIC TECHNIQUES; HEK293 CELLS; HUMANS; MICE; MICE, TRANSGENIC; NEURONS; RECEPTOR, MUSCARINIC M3; RECEPTOR, MUSCARINIC M4;

EID: 85026781248     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.aan2475     Document Type: Article

References (18)

1. B. N. Armbruster, X. Li, M. H. Pausch, S. Herlitze, B. L. Roth, Proc. Natl. Acad. Sci. U.S.A. 104, 5163–5168 (2007).
2. J. G. English, B. L. Roth, JAMA Neurol. 72, 1361–1366 (2015).
3. D. J. Urban, B. L. Roth, Annu. Rev. Pharmacol. Toxicol. 55, 399–417 (2015).
4. B. Ji et al., J. Neurosci. 36, 11544–11558 (2016).
5. A. Schotte et al., Psychopharmacology (Berl.) 124, 57–73 (1996).
6. D. A. A. MacLaren et al., eNeuro 3, e0219-16.2016 (2016).
7. M. W. Jann, Y. W. Lam, W. H. Chang, Arch. Int. Pharmacodyn. Ther. 328, 243–250 (1994).
8. W. H. Chang et al., Prog. Neuropsychopharmacol. Biol. Psychiatry 22, 723–739 (1998).
9. G. Lin, G. McKay, K. K. Midha, J. Pharm. Biomed. Anal. 14, 1561–1577 (1996).
10. J. M. Guettier et al., Proc. Natl. Acad. Sci. U.S.A. 106, 19197–19202 (2009).
11. M. A. Eldridge et al., Nat. Neurosci. 19, 37–39 (2016).
12. J. Raper et al., ACS Chem. Neurosci. 8, 1570–1576 (2017).
13. D. Bender, M. Holschbach, G. Stöcklin, Nucl. Med. Biol. 21, 921–925 (1994).
14. M. Michaelides et al., J. Clin. Invest. 123, 5342–5350 (2013).
15. A. H. Schinkel, E. Wagenaar, C. A. Mol, L. van Deemter, J. Clin. Invest. 97, 2517–2524 (1996).
16. W. M. Pardridge, Expert Opin. Drug Deliv. 13, 963–975 (2016).
17. S. V. Mahler et al., Nat. Neurosci. 17, 577–585 (2014).
18. J. Fang, Eur. J. Drug Metab. Pharmacokinet. 25, 109–114 (2000).